Infographic – Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors

Version 2 2022-06-14, 15:24

Version 1 2022-06-14, 09:10

figure

posted on 2022-06-14, 15:24 authored by Taylor & FrancisTaylor & Francis, Mercedes Porosnicu, Anne-Marie Quinson, Kate Crossley, Stephan Luecke, Ulrich M Lauer

Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors

Funding

Boehringer Ingelheim International GmbH

History

Usage metrics

Keywords

cancer clinical trials immunotherapy oncology oncolytic virus solid tumors

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC